

Schenk, Dale B.
Application No.: 09/322,289
Page 2

PATENT

a¹
ent of USSN 60/067,740, filed December 2, 1997, each of which is incorporated by reference in its entirety for all purposes.

IN THE CLAIMS:

a² Sub B1
1. (Amended) A method of preventing or treating a disease characterized by amyloid deposit in a patient, comprising administering to the patient an antibody that specifically binds to the amyloid deposit or a component thereof, in a regime effective to prevent or treat the disease.

a³ 30. (Amended) The method of claim 29, wherein the human immunized with A β peptide is the patient.

a⁴ 32. (Amended) The method of claim 1, wherein the antibody is administered intraperitoneally, orally, subcutaneously, intramuscularly, topically or intravenously.

Please add the following claims:

56. (New) The method of claim 1, wherein the antibody is administered at a site separated by the blood-brain barrier from the brain.

57. (New) The method of claim 1, wherein the antibody specifically binds to A β in dissociated form with a binding affinity of at least $10^7 M^{-1}$.

58. (New) The method of claim 56, wherein the antibody specifically binds to A β 41.

a⁵ 59. (New) The method of claim 1, wherein the administering of the antibody reduces levels of A β in the brain of the patient.

60. (New) The method of claim 1, wherein the administering of the antibody results in an amelioration of symptoms determined by a psychometric measure.

61. (New) The method of claim 60, wherein the psychometric measure is a Mini-Mental State Examination score.

62. (New) The method of claim 60, wherein the psychometric measure is an ADAS score.

63. (New) The method of any one of claims 60-62, further comprising determining the psychometric measure.